Gain Therapeutics (GANX) Competitors $1.88 +0.02 (+1.08%) Closing price 04:00 PM EasternExtended Trading$1.88 0.00 (0.00%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock GANX vs. PBYI, ALLO, TVRD, GALT, NMRA, VOR, IMMP, SCPH, ALEC, and TKNOShould you be buying Gain Therapeutics stock or one of its competitors? The main competitors of Gain Therapeutics include Puma Biotechnology (PBYI), Allogene Therapeutics (ALLO), Tvardi Therapeutics (TVRD), Galectin Therapeutics (GALT), Neumora Therapeutics (NMRA), Vor Biopharma (VOR), Prima BioMed (IMMP), scPharmaceuticals (SCPH), Alector (ALEC), and Alpha Teknova (TKNO). These companies are all part of the "pharmaceutical products" industry. Gain Therapeutics vs. Its Competitors Puma Biotechnology Allogene Therapeutics Tvardi Therapeutics Galectin Therapeutics Neumora Therapeutics Vor Biopharma Prima BioMed scPharmaceuticals Alector Alpha Teknova Gain Therapeutics (NASDAQ:GANX) and Puma Biotechnology (NASDAQ:PBYI) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, risk, analyst recommendations, media sentiment, profitability, valuation and dividends. Do analysts rate GANX or PBYI? Gain Therapeutics currently has a consensus target price of $7.80, indicating a potential upside of 314.89%. Puma Biotechnology has a consensus target price of $7.00, indicating a potential upside of 40.85%. Given Gain Therapeutics' higher probable upside, equities analysts plainly believe Gain Therapeutics is more favorable than Puma Biotechnology.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Gain Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00Puma Biotechnology 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more risk and volatility, GANX or PBYI? Gain Therapeutics has a beta of 0.1, suggesting that its share price is 90% less volatile than the S&P 500. Comparatively, Puma Biotechnology has a beta of 1.3, suggesting that its share price is 30% more volatile than the S&P 500. Do insiders and institutionals have more ownership in GANX or PBYI? 12.0% of Gain Therapeutics shares are held by institutional investors. Comparatively, 61.3% of Puma Biotechnology shares are held by institutional investors. 7.2% of Gain Therapeutics shares are held by insiders. Comparatively, 23.3% of Puma Biotechnology shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Is GANX or PBYI more profitable? Puma Biotechnology has a net margin of 20.38% compared to Gain Therapeutics' net margin of 0.00%. Puma Biotechnology's return on equity of 53.15% beat Gain Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Gain TherapeuticsN/A -289.10% -155.11% Puma Biotechnology 20.38%53.15%23.51% Which has preferable valuation & earnings, GANX or PBYI? Puma Biotechnology has higher revenue and earnings than Gain Therapeutics. Gain Therapeutics is trading at a lower price-to-earnings ratio than Puma Biotechnology, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGain Therapeutics$50K1,351.72-$20.41M-$0.63-2.98Puma Biotechnology$238.06M1.05$30.28M$0.985.07 Does the media prefer GANX or PBYI? In the previous week, Gain Therapeutics had 7 more articles in the media than Puma Biotechnology. MarketBeat recorded 9 mentions for Gain Therapeutics and 2 mentions for Puma Biotechnology. Puma Biotechnology's average media sentiment score of 1.78 beat Gain Therapeutics' score of 0.13 indicating that Puma Biotechnology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Gain Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Puma Biotechnology 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive SummaryPuma Biotechnology beats Gain Therapeutics on 11 of the 15 factors compared between the two stocks. Get Gain Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GANX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding GANX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GANX vs. The Competition Export to ExcelMetricGain TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$67.59M$2.79B$5.76B$9.84BDividend YieldN/A1.68%3.95%4.02%P/E Ratio-2.9822.8231.3126.60Price / Sales1,351.72742.71461.30121.37Price / CashN/A177.7737.7659.36Price / Book18.806.1810.026.67Net Income-$20.41M$32.94M$3.27B$265.59M7 Day Performance3.87%0.99%3.17%3.42%1 Month Performance16.05%1.69%4.34%1.09%1 Year Performance41.35%11.45%44.11%23.85% Gain Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GANXGain Therapeutics2.1818 of 5 stars$1.88+1.1%$7.80+314.9%+42.0%$67.59M$50K-2.9820News CoverageAnalyst RevisionPBYIPuma Biotechnology4.1355 of 5 stars$4.99-5.0%$7.00+40.3%+100.8%$264.45M$230.50M5.09200Positive NewsALLOAllogene Therapeutics2.8653 of 5 stars$1.16-2.5%$8.44+628.0%-56.7%$264.04MN/A-1.05310TVRDTvardi Therapeutics1.5746 of 5 stars$29.20+4.1%$64.25+120.0%N/A$263.04MN/A0.0080Gap DownGALTGalectin Therapeutics2.4098 of 5 stars$4.00-2.4%$6.00+50.0%+51.9%$262.65MN/A-6.259Positive NewsNMRANeumora Therapeutics2.5765 of 5 stars$1.63+0.6%$7.14+338.2%-84.8%$262.35MN/A-1.04108VORVor Biopharma1.8567 of 5 stars$2.06-5.1%$6.07+194.5%+124.7%$260.97MN/A-1.25140News CoverageInsider TradeGap UpIMMPPrima BioMed1.5152 of 5 stars$1.70-4.0%$7.00+311.8%-30.5%$259.81M$5.14M0.002,021Upcoming EarningsSCPHscPharmaceuticals4.2537 of 5 stars$5.52+13.8%$14.00+153.6%+7.2%$258.50M$36.33M-3.0530Analyst DowngradeHigh Trading VolumeALECAlector4.1252 of 5 stars$2.34-7.1%$4.17+78.1%-54.6%$255.05M$81.13M-2.02270News CoveragePositive NewsTKNOAlpha Teknova2.4287 of 5 stars$4.48-5.7%$10.00+123.2%-3.3%$254.20M$37.74M-10.67240 Related Companies and Tools Related Companies Puma Biotechnology Alternatives Allogene Therapeutics Alternatives Tvardi Therapeutics Alternatives Galectin Therapeutics Alternatives Neumora Therapeutics Alternatives Vor Biopharma Alternatives Prima BioMed Alternatives scPharmaceuticals Alternatives Alector Alternatives Alpha Teknova Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GANX) was last updated on 8/28/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredTrump’s national nightmare is hereAI is no longer just about chatbots — it’s becoming the backbone of the global economy. While U.S. firms push ...Porter & Company | SponsoredTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...Weiss Ratings | SponsoredIs This Stock the 'Next Nvidia'?'AI Bottleneck' Now Threatens Entire Magnificent 7 A new critical failure has appeared in the AI market, an...Altimetry | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Gain Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Gain Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access